Unity Biotech down 48% premarket on stumble with lead drug

Unity Biotechnology's (NASDAQ:UBX) lead candidate UBX0101, a p53/MDM2 interaction inhibitor, failed to sufficiently separate from placebo at week 12 in a Phase 2 clinical trial in patients with moderate-to-severe osteoarthritis of the knee. Specifically, there was no statistically significant difference between any of the three dose arms and the control arm as measured by the primary endpoint, a scale called WOMAC-A.